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RECENT progress in islet isolation and purification 
technology has contributed to the first successful 
cases of human islet transplantation. 1 The liver was used 
as the target organ of human islet allografts in most cases. 
Chronic failure of intraportally transplanted islets has been 
observed in both large animals and humans. leading inves-
tigators to question whether the liver is the ideal site for 
islet implantation. In a preliminary study, II dogs received 
intraportal islet autografts (13,000 to l6,()()() equivalent 
islets/kg of recipient body weight) following total pancre-
atectomy. 2 Failure of the islet grafts was observed within 
18 months in all animals (in preparation). 
Because nitric oxide (NO) toxicity to islets has been 
recently demonstrated,3 these results encouraged us to test 
whether hepatic cells can generate higher levels of NO 
during 24-hour culture in the presence of a cytokine 
mixture (interleukin [IL]-I, tumor necrosis factor [TNF]-
cr, interferon [IFN]-y) and LPS. 
The results indicated that hepatic cells were able to 
generate significantly higher levels of NO in response to 
the stimulatory mixture. independently from the presence 
or absence of islets.4 In contrast, islets with or without 
pancreatic exocrine tissue produced significantly lower 
levels of NO. The observation of chronic failure of intra-
hepatic islet transplants and the relative inability of the 
pancreas to generate NO in response to inflammatory 
cytokines encouraged us to test the pancreas as an alter-
native site for islet implantation in dogs. 
MATERIALS AND METHODS 
Seven mongrel dogs received islet autografts following partial 
pancreatectomy (3/4). The islets were separated by the automated 
method and purified on Eurocollins-Ficoll gradients using a 
COBE cell separator.· Purified islets (volume < I mL) were 
implanted into the residual pancreatic segment using a 27-gauge 
needle. Four weeks after autotransplantation. animals were killed 
for analysis of morphological integrity of the intrapancreatic islet 
grafts (hematoxylin eosin staining and immunoperoxidase staining 
for insulin). 
RESULTS AND DISCUSSION 
Intrapancreatic islet injection was uneventful. Amylase 
and glucose levels remained within the normal range for 
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the duration of the study. Large aggregates of well-pre-
served islet cells with a normal degree of /3-granulation 
were present at the sites of intrapancreatic islet infusion. 
Interestingly, no mononuclear cell infiltrate was present in 
the area of the implants. These results indicate that the 
pancreas could be an ideal site for transplantation of highly 
purified islet preparations. Studies are in progress to 
determine the functional integrity of intrapancreatic islet 
grafts and establish whether chronic failure of islet trans-
plants will be prevented in this alternative site. 
Chronic failure of intrahepatic islets even in autografts 
could be explained by continuous exposure to enteric 
pathogens and endotoxins that reach the liver through the 
portal circulation. This could result in generation of higher 
levels of NO. Stimulated NO generation by hepatic cells 
could also explain why multiple donors have been neces-
sary to normalize glucose levels after human islet trans-
plantation into an allogeneic liver. In this case, the local 
activation of antigen-presenting cells could generate high 
levels of NO in the microenvironment at the transplant 
site. 
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